The values obtained here highlight the quantitative repeatability of iMSI as an appropriate, fit-for-purpose method for analyzing dystrophin as a biomarker of therapeutic efficacy in DMD. The gene discussed is DMD; the disease is Duchenne muscular dystrophy.